Zuranolone

Molecular mass: 409.574 g/mol  PubChem compound: 86294073

Active ingredient description

The mechanism of action of zuranolone in the treatment of postpartum depression is not fully understood, but is thought to be related to its positive allosteric modulation of GABAA receptors.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
N06AX31 N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AX Other antidepressants
Discover more medicines within N06AX31

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
ZURZUVAE Capsule FDA, National Drug Code (US) MPI, US: SPL/PLR

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 1632051-40-1
DrugBank Drug: DB15490
KEGG Drug: D11793
PubChem Compound: 86294073
RxNorm Ingredient: 2669905
UNII Identifier: 7ZW49N180B
ZURANOLONE

Medicines

Zuranolone is an active ingredient of these brands:

United States (US)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.

 
Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈